Artelo Biosciences shares are trading higher after the company announced a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust, to be funded by Glaucoma UK and the HSC R&D Division. The study will evaluate the effects of Artelo's peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension. - Artelo Biosciences (NASDAQ:ARTL)
Published on March 18, 2026.
Artel Biosciences shares have surged after the company announced a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust, funded by Glaucoma UK and the HSC R&D Division. The study will examine the effects of Artel's peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucheche.
.
Related Articles
Tigress Financial Maintains Strong Buy on Meta Platforms, Raises Price Target to $945 - Meta Platforms (NASDAQ:META)
Tigher-Sheepen (formerly known as "Ethic" is the name of the day: An article by Steve N.
Telsey Advisory Group Maintains Market Perform on Macy's, Maintains $25 Price Target - Macy's (NYSE:M)
The article is published here:.
The stock market is quickly losing momentum and Fed decision won't help
The stock market is losing momentum as the S & P 500 struggles with rising volatility and a potential rise in US-Iran war-related tensions, with few expectations of interest rate cuts.